BioSante Offering to Support Female Sex Dysfunction Drug
By Catherine Shaffer
Monday, March 7, 2011
BioSante Pharmaceuticals Inc. said it will raise $25.1 million in a registered direct offering to support several ongoing clinical trials of its testosterone gel product, Libigel. Pursuant to a prior shelf registration, the Lincolnshire, Ill.-based company will sell 12.2 million shares of common stock and warrants to several institutional investors, with total net proceeds estimated at $23.8 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.